Clinical Trial Update: Pharmacokinetic Study of Icenticaftor in Participants With Hepatic Impairment [Phase 1]

View source ↗

Summary

Phase 1 pharmacokinetic study evaluating the impact of hepatic impairment on Icenticaftor pharmacokinetics has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Liver Failure

Drugs mentioned

• Icenticaftor

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Hepatic Failure | Phase 1 | Status: COMPLETED